Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Overview of attention for article published in Blood Advances, May 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet
twitter: 17 X users

bluesky: 4 Bluesky users

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 24 X posts from 17 X users, with an upper bound of 54,860 followers.

RT @RahulBanerjeeMD: 3/ And our @BloodAdvances work from US #MMsm consortium demonstrating low utility to 8-week driving restrictions with…

3/ And our @BloodAdvances work from US #MMsm consortium demonstrating low utility to 8-week driving restrictions with CAR-T for myeloma, including ide-cel (fixed) and cilta-cel (not quite yet). Others have investigated 2-week CRS monitoring as well. ht…

RT @Myeloma_Doc: #Myeloma Paper of the Day: US MM Immunotherapy Consortium study suggests universal driving restrictions beyond 4 weeks app…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 20 additional X posts.